Abstract

In the treatment of infertility by the method of fertilization in vitro , such a serious complication as ovarian hyperstimulation syndrome (OHSS) can occur. Primary predictors of OHSS development are widely used in practice while selecting controlled ovarian stimulation patterns. The identification and evaluation of secondary predictors of OHSS development is relevant. Aim. To identify and evaluate secondary predictors of OHSS in women at high risk of OHSS. Materials and methods. The study included 240 women at high risk of developing ovarian hyperstimulation syndrome, 63 of these women subsequently developed ovarian hyperstimulation syndrome, and 177 did not. To identify secondary predictors, a number of preovulatory follicles and oocytes was evaluated, estradiol levels, vascular endothelial growth factor (VEGF) and interleukin‑6 (IL‑6) were defined in the blood serum and follicular fluid. Results . Compared to women without OHSS, there was a statistically significant increase in the number of preovulatory follicles, oocytes, estradiol, VEGF, IL‑6 in the blood serum and follicular fluid in OHSS patients. There was a direct correlation between the serum and follicular fluid levels of estradiol (r s = 0.85; 95 % CI 0.80–0.89; P < 0.001), VEGF (r s = 0.76; 95 % CI 0.69–0.81; P < 0.001) and IL‑6 (r s = 0.67; 95 % CI 0.58–0.74; P < 0.001). Secondary predictors of OHSS was the number of preovulatory follicles ≥30 for two ovary (sensitivity – 46.0 %, specificity – 91.0 %), the number of oocytes ≥19 (sensitivity – 87.3 %, specificity – 97.7 %), serum estradiol levels ≥4800 pg/ml (sensitivity – 74.6 %, specificity – 96.6 %) and estradiol in follicular fluid – ≥725000 pg/ml (sensitivity – 98.4 %, specificity – 97.7 %), serum VEGF ≥ 30 pg/ml (sensitivity – 76.2 %, specificity – 98.3 %) and VEGF in follicular fluid ≥500 pg/ml (sensitivity – 87.3 %, specificity – 97.2 %), IL‑6 in serum ≥4 pg/ml (sensitivity – 65.1 %, specificity – 98.9 %) and IL‑6 in follicular fluid ≥8.5 pg/ml (sensitivity – 90.5 %, specificity – 98.3 %), respectively. Conclusions. The predictors of OHSS should be taken into account to reduce the risk of its development. In identifying secondary predictors of OHSS development, it is necessary to use preventive measures consisting in discontinuation of luteal phase support, vitrification of all embryos and their transfer in subsequent thawed cycles.

Highlights

  • In the treatment of infertility by the method of fertilization in vitro, such a serious complication as ovarian hyperstimulation syndrome (OHSS) can occur

  • Secondary predictors of OHSS was the number of preovulatory follicles ≥30 for two ovary, the number of oocytes ≥19, serum estradiol levels ≥4800 pg/ml and estradiol in follicular fluid – ≥725000 pg/ml, serum vascular endothelial growth factor (VEGF) ≥ 30 pg/ml and VEGF in follicular fluid ≥500 pg/ml, IL-6 in serum ≥4 pg/ml and IL-6 in follicular fluid ≥8.5 pg/ml, respectively

  • In identifying secondary predictors of OHSS development, it is necessary to use preventive measures consisting in discontinuation of luteal phase support, vitrification of all embryos and their transfer in subsequent thawed cycles

Read more

Summary

Methods

The study included 240 women at high risk of developing ovarian hyperstimulation syndrome, 63 of these women subsequently developed ovarian hyperstimulation syndrome, and 177 did not. A number of preovulatory follicles and oocytes was evaluated, estradiol levels, vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) were defined in the blood serum and follicular fluid. The study included 240 women at high risk of OHSS development taking into account the primary predictors such as: the number of antral follicles more than 20, the content of antimullerian hormone 5.5 ng/ml and more, polycystic ovary syndrome, OHSS during previous in vitro fertilization attempts. Definition of estradiol, vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) in the blood serum and follicular fluid were performed on the day of transvaginal follicle puncture. Using the electrochemiluminescent method and the reagents of Roche Diagnostics (Switzerland) company on an automated analyzer Cobas-e411 (Roche Diagnostics, Switzerland), estradiol concentration was determined; by immune-enzyme method using an immune-enzyme reader ImmunoChem-2100 (Hight Tehnology, USA), VEGF was investigated using the reagents of the company “BIO Tech Lab S” (USA) and IL-6 – of “Vector-Best” company (RF)

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call